Where Now For Italy’s Drug Price Transparency Crusade?
All Eyes On New Head of Drugs Agency
The signs suggest that Nicola Magrini, the new director general of the Italian medicines regulator, AIFA, will follow in the footsteps of his predecessor in fighting for transparency in drug pricing.
You may also be interested in...
AMD patients in the UK can legitimately be given compounded bevacizumab (Roche’s Avastin) after the appeals court said NHS trusts could offer a drug off-label for economic reasons where there were no safety or efficacy concerns.
Italy has so far borne the brunt of Europe’s growing coronavirus outbreak. Now it is offering patients the chance to access unauthorized medicines as part of efforts to stem the outbreak.
Countries across the EU have been joining forces over the past few years to discuss and collaborate on pharmaceutical policy issues. They are hoping among other things to secure more sustainable drug prices and get a better grasp on what new medicines are on the horizon.